NCT05030545View on ClinicalTrials.gov

Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study

PHASE4RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

October 31, 2026

Study Completion Date

February 28, 2027

Conditions
Primary AldosteronismHypertension
Interventions
DRUG

Eplerenone

After baseline cardiac imaging with PET and echocardiogram, participants will be treated with eplerenone for 6 months at a starting dose of 50mg daily and up to a maximally tolerated dose of 100mg daily, followed by repeat imaging with PET and echocardiogram.

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER